V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Sage Therapeutics Executive Compensation (FY24)

SAGE · Executive and director compensation, fiscal 2022 to 2024

The Sage Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (DEF 14A): April 24, 2025
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Sage Therapeutics brief$1,500Get the executive brief
214 figures on this page, cited to the filing that reported them. See the citations
Chief executive, fiscal 2024
◇
Barry Greene
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Barry Greene: $6,237,491 → $7,112,589 (14.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Sage Therapeutics' chief executive and what were they paid?
Barry Greene, Chief Executive Officer and President, received $7,112,589 in total compensation for fiscal 2024. Greene's total was 14.0% higher than the $6,237,491 reported for fiscal 2023.
Which companies are in Sage Therapeutics' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Agios Pharmaceuticals, Inc., Alector, Inc., Amicus Therapeutics, Inc. and Amylyx Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Gregory Shiferman
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Christopher Benecchi
Chief Operating Officer and Treasurer
◇—◇◇◇—◇◇
Anne Marie Cook
Former Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Kimi Iguchi
Former Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Gregory Shiferman
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry Greene
Chief Executive Officer and President
◇—◇◇◇—◇◇
Kimi Iguchi
Former Chief Financial Officer and Treasurer
Departed during or after this year
◇—◇◇——◇◇
Anne Marie Cook
Former Senior Vice President, General Counsel and Secretary
Departed during or after this year
◇—◇◇——◇◇
Laura Gault
Former Chief Medical Officer
Departed during or after this year
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Senior ViceOPTION◇——◇—◇◇
Senior VicePSU◇—◇—◇—◇
Senior ViceOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Barry GreeneOption◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Christopher BenecchiOption◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Laura GaultPSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
Gregory ShifermanPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Kimi IguchiPSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey M. Jonas
◇—◇——◇◇
Geno Germano
◇—◇———◇
James M. Frates
◇—◇———◇
Michael F. Cola
◇—◇———◇
Elizabeth Barrett
◇—◇———◇
Jessica Federer
◇—◇———◇
George Golumbeski
◇—◇———◇
Steven Paul
◇—————◇
Kevin P. Starr
◇—————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ACADIA Pharmaceuticals Inc. ACAD
  • Agios Pharmaceuticals, Inc. AGIO
  • Alector, Inc. ALEC
  • Amicus Therapeutics, Inc. FOLD
  • Amylyx Pharmaceuticals AMLX
  • Apellis Pharmaceuticals, Inc. APLS
  • Ardelyx ARDX
  • Axsome Therapeutics, Inc. AXSM
  • BioCryst Pharmaceuticals BCRX
  • Blueprint Medicines Corporation BPMC
  • Cerevel Therapeutics, Inc. CERE
  • CRISPR Therapeutics, Inc. CRSP
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Dynavax Technologies DVAX
  • Esperion Therapeutics ESPR
  • Exelixis, Inc. EXEL
  • FibroGen, Inc. symbol not shown
  • Halozyme Therapeutics, Inc. HALO
  • Harmony Biosciences Holdings, Inc. HRMY
  • Insmed, Inc. INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ironwood Pharmaceuticals IRWD
  • Mirati Therapeutics, Inc. MRTX
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Sorrento Therapeutics, Inc. ATXI
  • Supernus Pharmaceuticals, Inc. SUPN
  • Tarsus Pharmaceuticals TARS
  • Travere Therapeutics TVTX
  • Ultragenyx Pharmaceutical Inc. RARE
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Sage Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Sage Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Sage Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Sage Therapeutics' disclosed peer group is defensible, who names Sage Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
214 figures on this page, cited to the filing that reported them.
214 cited to the filing

Documents cited

  1. 0000950170-25-058060
    2024 Summary Compensation Table · EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at December 31, 2024
  2. 0001193125-24-110075
    2023 Summary Compensation Table
  3. 0001193125-23-122119
    2022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Sage Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/SAGE (accessed 2026).
Short form: data: Velarion

The Sage Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Sage Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Sage Therapeutics discloses

The companies named in SAGE's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Agios Pharmaceuticals, Inc.Alector, Inc.Amicus Therapeutics, Inc.Amylyx PharmaceuticalsApellis Pharmaceuticals, Inc.ArdelyxAxsome Therapeutics, Inc.BioCryst PharmaceuticalsBlueprint Medicines CorporationCerevel Therapeutics, Inc.CRISPR Therapeutics, Inc.Deciphera Pharmaceuticals, Inc.Dynavax TechnologiesEsperion TherapeuticsExelixis, Inc.Halozyme Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Insmed, Inc.Intra-Cellular Therapies, Inc.Ironwood PharmaceuticalsRhythm Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.Tarsus Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy